Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitar Shishkov

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Journal of Urology|April 29, 2026
Reply by AuthorsSandip M Prasad, Dimitar Shishkov, Nikola V Mihaylov, et al.
The Journal of Urology|March 25, 2026
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION TrialSandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.
The Journal of Urology|October 24, 2024
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)Sandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.
The Journal of Urology|August 7, 2023
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)Sandip M Prasad, William C Huang, Neal D Shore, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Journal of Urology|April 29, 2026
Reply by AuthorsSandip M Prasad, Dimitar Shishkov, Nikola V Mihaylov, et al.
The Journal of Urology|March 25, 2026
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION TrialSandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.
The Journal of Urology|October 24, 2024
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)Sandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.
The Journal of Urology|August 7, 2023
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)Sandip M Prasad, William C Huang, Neal D Shore, et al.
Pageof 1